Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $54 from $74 and keeps a Buy rating on the shares. The target reduction comes following its update from its ongoing Ph3 studies. The main takeaway is that things are *mostly* on track. Newly updated / slightly delayed is progress with the MAGNITUDE study of nex-z for ATTR-CM – the company has enrolled about 48% of the target number of patients so far though now plans to complete enrollment by early 2027 versus YE26 previously.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood’s ARK Investment buys 226K shares of Intellia Therapeutics today
- Positive Outlook on Intellia Therapeutics Despite Mild Adverse Event in Phase 3 Study
- Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating
- Intellia’s Phase 3 Programs Progress Unhindered Despite Safety Concerns
- Cathie Wood’s ARK Investment buys 201K shares of Intellia Therapeutics today